Eli Lilly: the trials and tribulations of antibody patents
Working in the biomedicine department at Eli Lilly, Duane Marks says his work entails “pretty much all aspects touching on IP relating to our biomedicines”. Through the course of his career Marks, who is patent counsel in bioproducts, has practised in numerous areas including diagnostics, research tools, and medical devices.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
29 May 2026 A US appeals court has thrown out a jury verdict against a South Korean medical device company, ruling that Insulet waited too long to bring its trade secret misappropriation claim.
26 May 2026 Two days of discussions at LSPN North America revealed an industry grappling with narrower patent claims, global strategy changes, AI disruption and tougher dealmaking conditions.
26 May 2026 Ahead of WIPR Trade Secrets West, Cooley partner Heidi Keefe says that for legal teams, caution—not business pressure—should be the priority.